Literature review of eosinophilic pneumonia induced by daptomycin

doi:10.19803/j.1672-8629.2022.07.13

Abstract

Abstract: Objective To explore the regularity and characteristics of daptomycin-induced adverse reactions, and to provide reference for clinical rational drug use. Methods Such databases as CNKI, Wanfang, VIP, and PubMed were searched for articles about daptomycin-induced ADR that had been published between January 1, 2004 and July 31, 2019. Data on conditions of patients, medications, occurrence of ADR and prognosis was statistically analyzed. Results A total of 29 articles involving 51 cases of daptomycin-induced ADR-eosinophilic pneumonia-were included in this study. In these cases, the ratio of males to females was 5.25∶1. Most of the ADR occurred among elderly patients, accounting for 54.91% (28/51). 27.45% (14/51) of these ADR occurred within one to two weeks of medication. The main clinical manifestations were eosinophilia, dyspnea and febrile. The risk factors of eosinophilic pneumonia in patients might be related to age and dosage rather than to gender, the ADR history and combination of drugs. Conclusion Daptomycin-induced ADR vary, which deserve the attention of clinicians, clinical pharmacists and nurses so as to improve the rational use of drugs, and ensure the safety of medication.

Key words: daptomycin, eosinophilic pneumonia, adverse drug reaction, literature analysis

CLC Number:

R994.11

SUN Bao, BAI Yanning, ZHANG Yuanyuan, QIAO Yi, YANG Zhifu, WANG Jingwen, WEN Aidong. Literature review of eosinophilic pneumonia induced by daptomycin[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 757-761.

References

[1] DEBONO M, BARNHART M, CARRELL CB, et al.A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation[J]. J Antibiot (Tokyo), 1987, 40(6): 761-777.
[2] MÜLLER A, WENZEL M, STRAHL H, et al. Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains[J]. Proc Natl Acad Sci U S A, 2016, 113(45): E7077-E7086.
[3] COBB E, KIMBROUGH RC, NUGENT KM, et al.Organizing pneumonia and pulmonary eosinophilic infiltration associated with daptomycin[J]. Ann Pharmacother, 2007, 41(4): 696-701.
[4] HAYES D JR, ANSTEAD MI, KUHN RJ.Eosinophilic pneumonia induced by daptomycin[J]. J Infect, 2007, 54(4): e211-e213.
[5] SHINDE A, SEIFI A, DELRE S, et al.Daptomycin-induced pulmonary infiltrates with eosinophilia[J]. J Infect, 2009, 58(2): 173-174.
[6] DOAN TL, DEPETRILLO J, SINGER C.Daptomycin-induced eosinophilia without pulmonary involvement[J]. Am J Health Syst Pharm, 2010, 67(24): 2107-2109.
[7] LAL Y, ASSIMACOPOULOS AP.Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis[J]. Clin Infect Dis, 2010, 50(5): 737-740.
[8] MILLER BA, GRAY A, LEBLANC TW, et al.Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases[J]. Clin Infect Dis, 2010, 50(11): e63-e68.
[9] KALOGEROPOULOS AS, TSIODRAS S, LOVERDOS D, et al.Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature[J]. J Med Case Rep, 2011, 5: 13.
[10] RETHER C, CONEN A, GROSSENBACHER M, et al.A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia[J]. Infection, 2011, 39(6): 583-585.
[11] KIM PW, SORBELLO AF, WASSEL RT, et al.Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports[J]. Drug Saf, 2012, 35(6): 447-457.
[12] PHILLIPS J, CARDILE AP, PATTERSON TF, et al.Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports[J]. Scand J Infect Dis, 2013, 45(10): 804-808.
[13] PATEL JJ, ANTONY A, HERRERA M, et al.Daptomycin-induced acute eosinophilic pneumonia[J]. WMJ, 2014, 113(5): 199-201.
[14] YAMAMOTO K, HAYAKAWA K, OHMAGARI N.Daptomycin-induced pneumonitis in a patient with chronic obstructive pulmonary disease (COPD)[J]. Intern Med, 2014, 53(21): 2559-2560.
[15] YUSUF E, PERROTTET N, ORASCH C, et al.Daptomycin-associated eosinophilic pneumonia in two patients with prosthetic joint infection[J]. Surg Infect (Larchmt), 2014,15(6): 834-837.
[16] FISHER LH, CHOI J, BRICKER RS, et al.Photo quiz. Daptomycin-induced eosinophilic pneumonia[J]. Clin Infect Dis, 2015, 61(6): 978-1027.
[17] CHIU SY, FAUST AC, DAND HM.Daptomycin-induced eosinophilic pneumonia treated with intravenous corticosteroids[J]. J Pharm Pract, 2015, 28(3): 275-279.
[18] HAGIYA H, HASEGAWA K, ASANO K, et al.Myopathy and eosinophilic pneumonia coincidentally induced by treatment with daptomycin[J]. Intern Med, 2015, 54(5): 525-529.
[19] ROUX S, FERRY T, CHIDIAC C, et al.Daptomycin-induced eosinophilic pneumonia[J]. Int J Infect Dis, 2015, 37: 95-96.
[20] AKCAER M, KARAKAS A, TOK D, et al.Eosinophilic pneumonia: Daptomycin-induced lung complication[J]. Med Mal Infect, 2016, 46(3): 166-168.
[21] HATIPOGLU M, MEMIS A, TURHAN V, et al.Possible daptomycin-induced acute eosinophilic pneumonia in a patient with diabetic foot infection[J]. Int J Antimicrob Agents, 2016, 47(5): 414-415.
[22] HIRAI J, HAGIHARA M, HARANAGA S, et al.Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature[J]. J Infect Chemother, 2017, 23(4): 245-249.
[23] ZACCARINI CG, DONG X.Poster 53 daptomycin-induced acute eosinophilic pneumonia in a patient receiving rehabilitation post prosthetic joint infection: a case report[J]. PMR, 2016, 8(9S): S178.
[24] RACHID M, AHMAD K, SAUNDERS-KURBAN M, et al.Daptomycin-induced acute eosinophilic pneumonia: late onset and quick recovery[J]. Case Rep Pulmonol, 2017, 2017: 8525789.
[25] HIGASHI Y, NAKAMURA S, TSUJI Y, et al.Daptomycin-induced eosinophilic pneumonia and a review of the published literature[J]. Intern Med, 2018, 57(2): 253-258.
[26] KUMAR S, ACOSTA-SANCHEZ I, RAJAGOPALAN N.Daptomycin- induced acute eosinophilic pneumonia[J]. Cureus, 2018, 10(6): e2899.
[27] RARU Y, ZEID F, BROWNING S, et al.Two patients with daptomycin induced eosinophilic pneumonia with different present-ations and treatment[J]. Respir Med Case Rep, 2017(23): 29-32.
[28] ABELENDA AG, MONTES RI, MARTÍN TJ, et al. Daptomycin eosinophilic pneumonia: an adverse effect to be aware of[J]. Rev Esp Quimioter, 2018, 31(3): 282-284.
[29] BASNET S, TACHAMO N, DHITAL R, et al.Daptomycin associated eosinophilic pneumonia: case report and differential diagnoses[J]. J Community Hosp Intern Med Perspect, 2018, 8(3): 152-155.
[30] RAZA A, ARSLAN A, ATIQ MU, et al.Unexpected outcome of daptomycin-induced eosinophilic pneumonia: rarity within a rarity[J]. Cureus, 2019, 11(12): e6271.
[31] STORANDT MH, MATTA A.Acute eosinophilic pneumonia: a rare complication of daptomycin therapy[J]. Cureus, 2020,12(1): e6803.
[32] OHNISHI H, ABE M, YOKOYAMA A, et al.Clarithromycin-induced eosinophilic pneumonia[J]. Intern Med, 2004, 43(3): 231-235.
[33] KLERKX S, PAT K, WUYTS W.Minocycline induced eosinophilic pneumonia: case report and review of literature[J]. Acta Clin Belg, 2009, 64(4): 349-354.
[34] PÉREZ-CASTRILLÓN JL, JIMÉNEZ-GARCÍA R, MARTÍN-ESCUDERO JC, et al. Roxithromycin-induced eosinophilic pneumonia[J]. Ann Pharmacother, 2002, 36(11): 1808-1809.
[35] ARBEIT RD, MAKI D, TALLY FP, et al.The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections[J]. Clin Infect Dis, 2004, 38(12): 1673-1681.
[36] ALLEN JN.Drug-induced eosinophilic lung disease[J]. Clin Chest Med, 2004, 25(1):77-88.
[37] KUO LC, LIN PC, WANG KF, et al.Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review[J]. Med Oncol, 2011, 28(1): 79-82.